医学
入射(几何)
人口
2型糖尿病
糖尿病
内科学
荟萃分析
低血糖
儿科
1型糖尿病
胰岛素
内分泌学
环境卫生
光学
物理
作者
Chloe Louise Edridge,Alison Dunkley,Danielle H. Bodicoat,Tanith C. Rose,Laura J. Gray,Melanie J. Davies,Kamlesh Khunti
出处
期刊:PLOS ONE
[Public Library of Science]
日期:2015-06-10
卷期号:10 (6): e0126427-e0126427
被引量:226
标识
DOI:10.1371/journal.pone.0126427
摘要
OBJECTIVE: To collate and evaluate the current literature reporting the prevalence and incidence of hypoglycaemia in population based studies of type 2 diabetes. RESEARCH DESIGN AND METHODS: Medline, Embase and Cochrane were searched up to February 2014 to identify population based studies reporting the proportion of people with type 2 diabetes experiencing hypoglycaemia or rate of events experienced. Two reviewers independently screened studies for eligibility and extracted data for included studies. Random effects meta-analyses were carried out to calculate the prevalence and incidence of hypoglycaemia. RESULTS: 46 studies (n = 532,542) met the inclusion criteria. Prevalence of hypoglycaemia was 45% (95%CI 0.34,0.57) for mild/moderate and 6% (95%CI, 0.05,0.07) for severe. Incidence of hypoglycaemic episodes per person-year for mild/moderate and for severe was 19 (95%CI 0.00, 51.08) and 0.80 (95%CI 0.00,2.15), respectively. Hypoglycaemia was prevalent amongst those on insulin; for mild/moderate episodes the prevalence was 50% and incidence 23 events per person-year, and for severe episodes the prevalence was 21% and incidence 1 event per person-year. For treatment regimes that included a sulphonylurea, mild/moderate prevalence was 30% and incidence 2 events per person-year, and severe prevalence was 5% and incidence 0.01 events per person-year. A similar prevalence of 5% was found for treatment regimes that did not include sulphonylureas. CONCLUSIONS: Current evidence shows hypoglycaemia is considerably prevalent amongst people with type 2 diabetes, particularly for those on insulin, yet still fairly common for other treatment regimens. This highlights the subsequent need for educational interventions and individualisation of therapies to reduce the risk of hypoglycaemia.
科研通智能强力驱动
Strongly Powered by AbleSci AI